Skip to main content

Advertisement

Fig. 3 | BMC Cancer

Fig. 3

From: Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation

Fig. 3

Cost-Effectiveness plane of the quality adjusted life years (QALYs) per costs of the TIL treatment versus ipilimumab. The scatter plot is showing the mean differences in costs and outcomes from the data using 10,000 bootstrap replicates. Fifty-six percent of the dots are in the South-East quadrant which indicates that the TIL treatment is in most cases less expensive and more effective compared to ipilimumab

Back to article page